SEC Form 4 · accession 0000950138-18-000313
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven J. Romano
Officer — Exec. VP & Chief Sci. Ofcr
Period of report
Apr 2, 2018
Accepted (ET)
Apr 4, 2018 · 6:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Apr 2, 2018 | A | 36,232 | $0.00 | A | 59,663 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F3 | $13.80 | Apr 2, 2018 | A | 189,201 | A | Apr 2, 2019 | Apr 2, 2028 | Ordinary Shares | 189,201 | 189,201 | D |
Explanation of responses
- F1Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019.
- F2Includes 842 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan.
- F3The options vest in four equal annual installments beginning April 2, 2019.